Fig. 1: The PI3K/AKT/mTOR pathway is active in hepatocellular carcinoma. | Cell Death & Disease

Fig. 1: The PI3K/AKT/mTOR pathway is active in hepatocellular carcinoma.

From: The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma

Fig. 1

A Oncoprinter showed the distribution and frequency of PI3K/AKT/mTOR pathway-related gene mutations, copy number changes, and gene expression levels in liver cancer samples. B Analysis of survival differences in patients with liver cancer with PI3K/AKT/mTOR gene mutations from TCGA database (data source: https://www.cbioportal.org/).

Back to article page